Jan Nuzhat, Guy Christopher, Reshko Leonid B, Hugo Geoffrey D, Weiss Elisabeth
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia.
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia.
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):683-690. doi: 10.1016/j.ijrobp.2017.02.227. Epub 2017 Mar 8.
To investigate the hypothesis that positional and anatomic variations during radiation therapy induce changes in lung and heart volumes and associated radiation doses.
In this longitudinal investigation, variations in lung and heart volumes and standard dose parameters of mean lung dose, lung V, mean heart dose, and heart V were analyzed on weekly 4-dimensional CT scans of 15 lung cancer patients during conventionally fractionated radiochemotherapy. Tumor, individual lung lobes, and heart were delineated on the mid-ventilation phase of weekly 4-dimensional CT scans. Lung lobes and heart were also contoured on individual breathing phases of pre-, mid-, and end-of-treatment scans. Planning dose was transferred to consecutive scans via rigid registration. Volume and dose variations were assessed relative to the initial planning scan.
Interfraction lung volume variability relative to week 0 was twice as large as tidal volume variability (8.0% ± 5.3% vs 4.0% ± 3.3%, P=.003). Interfraction lung volume variation ranged between 0.8% and 17.1% for individual patient means. Lower lung lobes had larger volume variability compared with upper lobes (13.5% ± 8.1% vs 7.0% ± 5.0%, P<.00001). Average mean lung dose variation was 0.5 Gy (range, 0.2-1.0 Gy for individual patient means) and average lung V variation 0.9% (range, 0.2%-1.6%). Average heart volume variation was 7.2% (range, 3.4%-12.6%). Average mean heart dose variation was 1.2 Gy (range, 0.1-3.0 Gy) and average heart V variation 1.4% (range, 0%-4.2%).
Anatomic and positional variations during radiation therapy induce changes in radiation doses to lung and heart. Repeated lung and heart dose assessment will provide a better estimate of the actual delivered dose and will improve prediction models for normal tissue toxicity, if assessed in larger cohorts.
研究放疗期间的位置和解剖学变化是否会引起肺和心脏体积以及相关辐射剂量的改变这一假设。
在这项纵向研究中,对15例肺癌患者在常规分割放化疗期间每周进行的四维CT扫描进行分析,以观察肺和心脏体积的变化以及平均肺剂量、肺V、平均心脏剂量和心脏V等标准剂量参数的变化。在每周四维CT扫描的通气中期对肿瘤、各个肺叶和心脏进行勾画。在治疗前、中期和末期扫描的各个呼吸阶段也对肺叶和心脏进行轮廓勾画。通过刚性配准将计划剂量转移到连续扫描图像上。相对于初始计划扫描评估体积和剂量变化。
与潮气量变化相比,相对于第0周,分次间肺体积变异性是其两倍(8.0%±5.3%对4.0%±3.3%,P = 0.003)。个体患者平均值的分次间肺体积变化范围在0.8%至17.1%之间。下肺叶的体积变异性比上肺叶大(13.5%±8.1%对7.0%±5.0%,P < 0.00001)。平均平均肺剂量变化为0.5 Gy(个体患者平均值范围为0.2 - 1.0 Gy),平均肺V变化为0.9%(范围为0.2% - 1.6%)。平均心脏体积变化为7.2%(范围为3.4% - 12.6%)。平均平均心脏剂量变化为1.2 Gy(范围为0.1 - 3.0 Gy),平均心脏V变化为1.4%(范围为0% - 4.2%)。
放疗期间的解剖学和位置变化会引起肺和心脏辐射剂量的改变。如果在更大队列中进行评估,重复进行肺和心脏剂量评估将能更好地估计实际给予的剂量,并改善正常组织毒性的预测模型。